Anti-CD19 CAR T Infusion Combined With Allogeneic Stem Cell Transplantation for B-cell Leukemia/Lymphoma

Inclusion Criteria:

* 5 Years to 70 Years, Male and female;
* Expected survival \> 12 weeks;
* Performance score 0-2;
* Histologically confirmed as CD19-positive lymphoma/leukemia and who meet one of the following conditions; Patient receive at least 2-4 prior combination chemotherapy regimens (not including single agent monoclonal antibody therapy) and fail to achieve CR; or have disease recurrence; or not eligible for allogeneic stem cell transplantation; or disease responding or stable after most recent therapy but refused further treatment; Disease recurrence after stem cell transplantation; Diagnosis as lymphoma, but refuse conventional treatment such as chemotherapy, radiation, stem cell transplantation and monoclonal antibody therapy
* Creatinine \< 2.5 mg/dl;
* ALT/AST \< 3x normal;
* Bilirubin \< 2.0 mg/dl;
* Adequate venous access for apheresis, and no other contraindications for leukapheresis;
* Take contraceptive measures before recruit to this trial;
* Written voluntary informed consent is given.

Exclusion Criteria:

* Patients with symptoms of central nervous system
* Accompanied by other malignant tumor
* Active hepatitis B or C, HIV infection
* Any other diseases could affect the outcome of this trial
* Suffering severe cardiovascular or respiratory disease
* Poorly controlled hypertension
* A history of mental illness and poorly controlled
* Taking immunosuppressive agents within 1 week due to organ transplantation or other disease which need long-lasting administration
* Occurrence of unstable pulmonary embolism, deep vein thrombosis, or other major arterial/venous thromboembolic events 30 days prior to assignment
* Reaching a steady dose if receiving anticoagulant therapy before assignment
* Female study participants of reproductive potential must have a negative serum or urine pregnancy test performed within 48 hours before infusion
* Pregnant or lactating women
* Subject suffering disease affects the understanding of informed consent or comply with study protocol.